Efficacy and safety of systemic, high-dose glucocorticoid therapy for idiopathic sudden sensorineural hearing loss
Background Systemic glucocorticosteroids (“steroids”) are widely used worldwide as a standard of care for primary therapy of idiopathic sudden sensorineural hearing loss (ISSHL). The German ISSHL guideline recommends high-dose steroids without evidence from randomized controlled trials (RCTs) and refers solely to retrospective cohort studies. This RCT aims to assess the efficacy (improvement in hearing) and safety (especially systemic side effects) of high-dose steroids versus standard of care (standard dose systemic steroids) for the treatment of unilateral ISSHL, when given as a primary therapy. Methods The study is designed as a multicenter (approximately 40 centers), randomized, triple-blind, three-armed, parallel group, clinical trial with 312 adult patients. The interventions consist of 5 days of 250 mg/day intravenous prednisolone (intervention 1) + oral placebo, or 5 days of 40 mg/day oral dexamethasone (intervention 2) + intravenous placebo. The control intervention consists of 60 mg oral prednisolone for 5 days followed by five tapering doses + intravenous placebo. The primary efficacy endpoint is the change in hearing threshold in the three most affected contiguous frequencies between 0.25 and 8 kHz 1 month after ISSHL. Secondary endpoints include further measures of hearing improvement including speech audiometry, tinnitus, quality of life, blood pressure, and altered glucose tolerance. Discussion There is an unmet medical need for an effective medical therapy of ISSHL. Although sensorineural hearing impairment can be partially compensated by hearing aids or cochlear implants (CI), generic hearing is better than using hearing aids or CIs. Since adverse effects of a short course of high-dose systemic corticosteroids have not been documented with good evidence, the trial will improve knowledge on possible side effects in the different treatment arms with a focus on hyperglycemia and hypertension. Trial registration EudraCT (European Union Drug Regulating Authorities Clinical Trials Database) Nr. 2015-002602-36; Sponsor code: KKSH-127..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:70 |
|---|---|
| Enthalten in: |
HNO - 70(2022), Suppl 2 vom: 20. Juni, Seite 30-44 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Plontke, Stefan K. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Corticosteroids |
|---|
| RVK: |
|---|
| Anmerkungen: |
© The Author(s) 2022 |
|---|
| doi: |
10.1007/s00106-022-01184-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2079082272 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2079082272 | ||
| 003 | DE-627 | ||
| 005 | 20240118102945.0 | ||
| 007 | tu | ||
| 008 | 221220s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00106-022-01184-8 |2 doi | |
| 035 | |a (DE-627)OLC2079082272 | ||
| 035 | |a (DE-He213)s00106-022-01184-8-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a XA 45800 |q VZ |2 rvk | ||
| 100 | 1 | |a Plontke, Stefan K. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of systemic, high-dose glucocorticoid therapy for idiopathic sudden sensorineural hearing loss |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s) 2022 | ||
| 520 | |a Background Systemic glucocorticosteroids (“steroids”) are widely used worldwide as a standard of care for primary therapy of idiopathic sudden sensorineural hearing loss (ISSHL). The German ISSHL guideline recommends high-dose steroids without evidence from randomized controlled trials (RCTs) and refers solely to retrospective cohort studies. This RCT aims to assess the efficacy (improvement in hearing) and safety (especially systemic side effects) of high-dose steroids versus standard of care (standard dose systemic steroids) for the treatment of unilateral ISSHL, when given as a primary therapy. Methods The study is designed as a multicenter (approximately 40 centers), randomized, triple-blind, three-armed, parallel group, clinical trial with 312 adult patients. The interventions consist of 5 days of 250 mg/day intravenous prednisolone (intervention 1) + oral placebo, or 5 days of 40 mg/day oral dexamethasone (intervention 2) + intravenous placebo. The control intervention consists of 60 mg oral prednisolone for 5 days followed by five tapering doses + intravenous placebo. The primary efficacy endpoint is the change in hearing threshold in the three most affected contiguous frequencies between 0.25 and 8 kHz 1 month after ISSHL. Secondary endpoints include further measures of hearing improvement including speech audiometry, tinnitus, quality of life, blood pressure, and altered glucose tolerance. Discussion There is an unmet medical need for an effective medical therapy of ISSHL. Although sensorineural hearing impairment can be partially compensated by hearing aids or cochlear implants (CI), generic hearing is better than using hearing aids or CIs. Since adverse effects of a short course of high-dose systemic corticosteroids have not been documented with good evidence, the trial will improve knowledge on possible side effects in the different treatment arms with a focus on hyperglycemia and hypertension. Trial registration EudraCT (European Union Drug Regulating Authorities Clinical Trials Database) Nr. 2015-002602-36; Sponsor code: KKSH-127. | ||
| 650 | 4 | |a Corticosteroids | |
| 650 | 4 | |a Dexamethasone | |
| 650 | 4 | |a Glucocorticoids | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Idiopathic | |
| 650 | 4 | |a Prednisolone | |
| 650 | 4 | |a Randomized controlled trial | |
| 650 | 4 | |a Steroids | |
| 650 | 4 | |a Sudden hearing loss | |
| 700 | 1 | |a Girndt, Matthias |4 aut | |
| 700 | 1 | |a Meisner, Christoph |4 aut | |
| 700 | 1 | |a Böselt, Iris |4 aut | |
| 700 | 1 | |a Ludwig-Kraus, Beatrice |4 aut | |
| 700 | 1 | |a Richter, Michael |4 aut | |
| 700 | 1 | |a Rahne, Torsten |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t HNO |d Springer Medizin, 1947 |g 70(2022), Suppl 2 vom: 20. Juni, Seite 30-44 |w (DE-627)129457167 |w (DE-600)200040-4 |w (DE-576)014820528 |x 0017-6192 |7 nnns |
| 773 | 1 | 8 | |g volume:70 |g year:2022 |g number:Suppl 2 |g day:20 |g month:06 |g pages:30-44 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s00106-022-01184-8 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a GBV_ILN_267 | ||
| 912 | |a GBV_ILN_2002 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_2018 | ||
| 912 | |a GBV_ILN_2414 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4277 | ||
| 936 | r | v | |a XA 45800 |
| 951 | |a AR | ||
| 952 | |d 70 |j 2022 |e Suppl 2 |b 20 |c 06 |h 30-44 | ||